Prevention of Cardiovascular Diseases: New Opportunities and Prospects
The article presents the main recommendations of cardiovascular messages for the prevention of cardiovascular diseases (CVD) in the clinical practice of cardiology in 2021. Recommendations «what to do and what not to do» for regular and secondary prevention of CVD, depending on cardiovascular risk (CVR), the presence and severity of comorbid diseases and risk factors (RF), are overviewed. The preference for simplifying schemes and regimens of drug aspect of prevention through a wider use of fixed combinations (FC) of antihypertensive (AHT) medicinal products (MP) and polypills, including AHT and lipid- lowering drugs, is reflected. The analysis of the substantiation and effectiveness of the use of a polypill containing perindopril, indapamide and rosuvastatin was carried out, taking into account the available evidence base.